IL25抗体;IL25 Antibody—艾普蒂

+ +

•  

   

     0    

  
  

Interleukin-25 (IL-25), a member of the IL-17 cytokine family (specifically IL-17E), is primarily produced by epithelial cells, eosinophils, mast cells, and other immune cells. It plays a critical role in promoting type 2 immune responses, which are associated with allergic inflammation, parasitic infections, and tissue repair. IL-25 binds to a heterodimeric receptor complex (IL-17RA/IL-17RB) on target cells, activating downstream signaling pathways like NF-κB and STAT3. leading to the production of type 2 cytokines (e.g., IL-4. IL-5. IL-13) and recruitment of eosinophils and basophils. Dysregulated IL-25 signaling is implicated in asthma, atopic dermatitis, and autoimmune disorders.

IL-25 antibodies are therapeutic or research tools designed to neutralize IL-25 activity. Monoclonal antibodies targeting IL-25 or its receptors aim to block this pathway, thereby reducing type 2 inflammation. Preclinical studies show their potential in alleviating symptoms of allergic diseases and autoimmune conditions. For example, anti-IL-25 antibodies have demonstrated efficacy in reducing airway hyperresponsiveness in asthma models and mitigating skin inflammation in atopic dermatitis. Clinical trials are ongoing to evaluate their safety and therapeutic potential in humans. These antibodies represent a promising strategy for precision immunotherapy, offering targeted modulation of pathogenic immune responses with fewer systemic side effects compared to broad immunosuppressants.